Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

Pharmaceutical Investing

Cyclacel Pharmaceuticals (NASDAQ:CYCC) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the receipt of a notice from the European Patent Office of the intention to grant a patent (EP1962814) including claims to novel pharmaceutical formulations of sapacitabine. As …

As quoted in the press release:

“This European notice of grant enhances the intellectual property estate related to sapacitabine. The relevant patent family is an important layer of our strategy of building on sapacitabine’s exclusivity. It supplements existing composition of matter, dosing regimen and combination treatment patent protection in major global markets extending into 2030,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

Click here to read the full press release.

cancer cyclacel pharmaceuticals european patent european patent office patent patent protection treatment of cancer Pharmaceutical Investing